Texas Pharmacy Greenwich Rx Recalls 10 Lots of Compounded Glutathione Injection Nationwide Over Elevated Endotoxin

Another Texas compounding pharmacy has pulled injectable glutathione off the market. On October 1, 2026, Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, announced a voluntary nationwide recall of 10 lots of compounded glutathione injection because of potential elevated endotoxin levels. The pharmacy says it is carrying out the recall with the knowledge of the U.S. Food and Drug Administration (FDA).

The action lands in the middle of a wider federal concern. Several Texas pharmacies recalled injectable glutathione over endotoxin earlier in 2026, and the U.S. Centers for Disease Control and Prevention (CDC) and the FDA have been investigating a multistate cluster of illnesses tied to the product. This piece sets out what Greenwich Rx recalled and why, what the recall notice does and does not claim, and how the product reaches patients through telehealth and wellness channels.

What Greenwich Rx recalled

The recalled product is Greenwich Rx compounded Glutathione Injection at a strength of 200 mg/mL, packaged in 10 mL multidose vials and formulated for subcutaneous injection. The recall covers 10 lots with beyond-use dates running from October 2, 2026 to November 12, 2026:

• Lot 0060-062426-1 (beyond-use date 10/02/2026)
• Lot 0060-062726-1 (10/05/2026)
• Lot 0060-070926-1 (10/17/2026)
• Lot 0060-071426-1 (10/22/2026)
• Lot 0060-071426-2 (10/22/2026)
• Lot 0060-072026-1 (10/28/2026)
• Lot 0060-072726-1 (11/04/2026)
• Lot 0060-072926-1 (11/06/2026)
• Lot 0060-073126-1 (11/08/2026)
• Lot 0060-080426-1 (11/12/2026)

Compounded injectable glutathione is not an FDA-approved drug product. Its quality depends on the compounding pharmacy that prepares it and on the grade of the ingredients used, which is why the source and handling of the product carry safety weight that an over-the-counter oral supplement does not.

Why the pharmacy is recalling the product

Greenwich Rx attributes the recall to potential elevated endotoxin levels. In the notice, the company states that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock, and death.

Endotoxins are fragments of certain bacteria. They can set off a strong inflammatory response when they enter the bloodstream even when no live organism is present, which is how an injectable can trigger fever, a drop in blood pressure, and sepsis-like symptoms without an active infection. Injection bypasses the skin and other barriers that normally guard against toxins, so an endotoxin problem in an injectable carries more direct risk than the same substance would taken by mouth.

The two emergency department reports

The recall notice includes two reports involving patients who received emergency department care following intravenous administration of a glutathione product that was not formulated for intravenous use. The recalled vials were formulated for subcutaneous injection, a shallow injection under the skin, not for delivery into a vein.

Two points are worth keeping distinct. The reported emergency visits followed administration by a route the product was not designed for. The recall itself rests on a separate finding, the potential for elevated endotoxin. The notice does not state that endotoxin caused the two emergency department visits, and it does not describe the patients' outcomes beyond the fact that they received emergency care.

How the product reached patients

Greenwich Rx says the affected lots were distributed to patients nationwide between June 26 and September 21, 2026, shipped directly to patients by the pharmacy. Injectable glutathione, along with combination drips, is commonly marketed through IV therapy and longevity clinics and telehealth wellness providers for energy, antioxidant support, skin lightening, and detox claims.

A direct-to-patient, mail-order model changes how a recall plays out. A patient who received vials by mail may have no local pharmacist to consult and may be several steps removed from the pharmacy that compounded the product. When reaching each recipient depends on the pharmacy's own records and outreach, follow-through on a recall is harder than it is for a drug dispensed over a pharmacy counter.

Where this fits in the 2026 glutathione recalls

The Greenwich Rx recall is the latest in a series of 2026 Texas compounding pharmacy recalls of injectable glutathione over elevated endotoxin. Earlier recalls this year came from other Texas pharmacies, and in September the CDC said it was working with the FDA, state and local health departments, and state boards of pharmacy to investigate a multistate cluster of illnesses in people who received injectable glutathione compounded from an ingredient labeled for dietary supplement use rather than for injection.

As of September 15, 2026, the CDC reported more than 25 people ill across at least four states, with at least three hospitalized and no deaths. In a separate communication dated August 27, 2026, the FDA said it was aware of at least 30 patients who had adverse events after intravenous glutathione, and it identified dietary supplement grade glutathione from Medisca Inc. of Plattsburgh, New York, including Lot #229536, as a common ingredient obtained by multiple compounding pharmacies. Those counts come from different agencies at different dates and should not be added together.

The Greenwich Rx notice does not name an ingredient supplier or an active ingredient lot, and it does not say whether its product is connected to the Medisca ingredient the FDA flagged. Whether this recall is part of the same ingredient problem is not established on the record of the notice itself.

What this means

A single pharmacy recall is a contained action. A fourth or later recall of the same product category, for the same stated hazard, inside an open CDC and FDA investigation, points to a market-wide quality question rather than one bad batch. The through line in the agencies' public statements is the grade of the glutathione being compounded: ingredients intended for dietary supplements are not made to the standard required for sterile injectables, and the FDA has told compounders not to use them for injection. The repeated endotoxin findings are consistent with that warning, though each recall notice stands on its own facts.

What patients and clinicians can do

This is general information, not medical advice. Decisions about any specific product or symptom should be made with a licensed clinician. Based on the recall notice and the agencies' published guidance:

• Patients who received Greenwich Rx glutathione injection should check their vials against the recalled lot numbers and contact the pharmacy's recall administrator, Sedgwick, at (866) 552-4916 or GreenwichRx7542@sedgwick.com for return and disposal instructions.
• Before receiving any injectable glutathione or IV drip, ask the provider whether the product was made with ingredients intended for injection and about any recalls or safety warnings.
• Clinicians should confirm the route a compounded product is formulated for, since the recalled vials were intended for subcutaneous use, not intravenous use.
• Report symptoms such as fever, chills, nausea, or injection-site reactions to a healthcare provider, and report adverse events to the FDA's MedWatch program at 1-800-332-1088.

What remains unverified

The recall is voluntary and, at the time of the announcement, had not been assigned an FDA recall classification. The notice reports two emergency department visits but does not tie them to endotoxin or describe patient outcomes, and it names no ingredient supplier. How many vials are in circulation, whether additional lots or states are drawn in, and how firmly this pharmacy's product connects to the broader CDC and FDA investigation are open questions the published record does not yet answer.